Intracranial Arteriosclerosis

Having a heart attack significantly increases the risk of developing other serious long-term health conditions, a major new study shows. Researchers analyzed more than 145 million records covering every adult patient admitted to hospital in England over a nine-year period to establish the risk of long-term health outcomes following a heart attack -- in the largest study of its kind. Up to a third of patients went on to develop heart or kidney failure, 7% had further heart attacks and 38% died from any cause within the nine-year study period. Heart failure, atrial fibrillation, stroke, peripheral arterial disease, severe bleeding, kidney failure, type 2 diabetes and depression all occurred more frequently for people who had a heart attack compared with those who did not. Having a heart attack significantly increases the risk of developing other serious long-term health conditions, a major new study shows. Researchers at the University of Leeds have analysed more than 145 million records covering every adult patient admitted to hospital over a nine-year period to establish the risk of long-term health outcomes following a heart attack -- in the largest study of its kind. Whilst heart attacks are a serious and life-threatening condition, the British Heart Foundation estimates that nowadays more than seven in 10 people survive them, provided they receive quick and emergency treatment to get the blood flowing to the heart muscle again. Yet previous research has shown that heart attacks can have health implications for patients including further conditions which affect the heart and circulatory system, but also conditions affecting other parts of the body and mental health conditions. The new research, part funded by The British Heart Foundation and Wellcome, shows that patients who had a heart attack went on to develop further conditions at a much higher rate than people of the same age and sex who had not had one. Up to a third of patients went on to develop heart or kidney failure, 7% had further heart attacks and 38% died from any cause within the nine-year study period. Heart failure, atrial fibrillation, stroke, peripheral arterial disease, severe bleeding, kidney failure, type 2 diabetes and depression all occurred more frequently for people who had a heart attack compared with those who did not; but the risk of cancer was lower overall, and the risk of dementia did not differ overall. The study also identified that people from more socioeconomically deprived backgrounds were more likely to die or develop serious long-term health conditions following a heart attack. In particular, those from more deprived backgrounds were more likely to develop heart and kidney failure, compared to people from less deprived backgrounds of a similar age. Lead author Dr Marlous Hall, Associate Professor of Cardiovascular Epidemiology in Leeds' School of Medicine and Multimorbidity Research in the Leeds Institute for Data Analytics (LIDA), said: "There are around 1.4 million heart attack survivors in the UK who are at high risk of developing further serious health conditions. Our study provides accessible online information of the risk of these health outcomes for specific age, sex and socioeconomic deprivation groups so that individuals surviving a heart attack can be well informed about their future risks, in order to support informed healthcare decision making with their doctor. "Effective communication of the likely course of disease and risk of adverse long-term outcomes between patients and healthcare professionals can promote positive lifestyle changes, encourage patients to stick to treatment, and improve patient understanding and quality of life." "Our study highlights the need for individual care plans to be revised to take into account the higher demand for care caused by survivorship." The researchers analysed the records of all individuals aged 18 years and over, who were admitted to one of 229 NHS Trusts in England between 1 January 2008 and 31 January, 2017. This amounted to 145,912,852 hospitalisations among 34,116,257 individuals. There were 433,361 reports of people who had a heart attack for the first time. The average age of heart attack patients was 67 years, and 66% of patients were male. The study looked at 11 non-fatal health outcomes detailed below, plus death from any cause, and compared the results to a control group of 2,001,310 individuals. Health outcomes The research showed a significantly increased risk of developing some conditions following a heart attack, when compared to the control group of patients. Most likely was heart failure, with 29.6% of the study group going on to develop the condition within nine years of their heart attack, compared with 9.8% of the control group over the same time frame. Kidney failure developed in 27.2% of the patients in the study group, compared with 19.8% of the control group. Some 22.3% of the study group went on to develop atrial fibrillation, compared with 16.8% of the control group. And new hospitalisation for diabetes was seen in 17% of the study group, compared with 14.3% of the control group. Other conditions were: Severe bleeding -- Study group: 19%; Control group: 18.4% Cerebrovascular disease -- Study group: 12.5%; Control group: 11.6% Peripheral arterial disease -- Study group: 6.5%; Control group: 4.06% Death from any cause -- Study group: 37.8%; Control group: 35.3% Overall, hospitalisation records indicating depression occurred in 8.9% of people after a heart attack -- which was 6% more likely following a heart attack than in the control group. Women were more likely to develop depression after a heart attack than men, especially those who had their heart attack at a younger age. 21.5% of women who were under the age of 40 at the time of their heart attack had hospitalisation records for depression compared with 11.5% of men in the same age category. There was no overall difference in the risk of dementia following a heart attack compared with the control group. Whilst the risk of vascular dementia was more likely in the study group, the difference observed was small (study group 2.3%; control group 2.1%). In contrast with other health outcomes the research showed that cancer was less pronounced in the study group than in the control group. Some 13.5% of the study group went on to develop cancer after their heart attack, but this compared with 21.5% of the control group. Researchers believe there are likely many factors affecting this finding but the specific reasons for fewer cancers after a heart attack remain unclear and require further investigation. Morag Foreman, Head of Discovery Researchers at Wellcome, said: "This research provides valuable insight into the types of support and interventions that may be needed for patients following a heart attack, helping both doctors and patients make informed decisions during recovery and beyond." "This research shows how cohort studies and analysis of large data sets can further our understanding of key health challenges and demonstrates the value to supporting discovery research in the field of population and public health. As survival rates following a heart attack improve, understanding the longer-term impacts on physical and mental health is crucial." Professor Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, said: "While more people than ever are surviving heart attacks, there can be longer term consequences. Particularly after a major heart attack, people can be left with irreparable damage to their heart, putting them at increased risk of heart failure. "This study sheds further light on how heart attacks are associated with increased risk of developing other serious health conditions, including heart failure and atrial fibrillation. It also found that those from more socioeconomically deprived backgrounds are at greater risk of further ill health after a heart attack, and at a younger age. The research suggests that these patients may benefit from additional support and monitoring to help reduce their risk of developing further health conditions. "It is vital NHS has the resource, including staff, infrastructure and equipment, to deliver the care that patients need to help them stay in the best possible health for longer."

VÉLIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- The MEDITWIN consortium was announced on December 11, 2023, in the presence of French President Emmanuel Macron. More details were presented at the PariSanté Campus on December 14 in the presence of French Minister Delegate for Industry Roland Lescure. The consortium is made up of seven University Hospital Institutes (IHUs), Nantes University Hospital (CHU), Inria, startups and Dassault Systèmes. MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all. The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment. In particular, MEDITWIN will enable doctors to simulate future scenarios for a patient. Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology. This will result in seven "virtual healthcare products" that will be deployed on a sovereign industrial cloud platform. The MEDITWIN project leverages the expertise of world-class partners in each of the fields covered, around the 14 founding members of this consortium: Dassault Systèmes, as the industrial leader of the consortium; seven University Hospital Institutes at the highest level of medical and scientific excellence; Nantes University Hospital via l’institut du thorax; startups inHEART, Codoc, Qairnel and Neurometers; and Inria through 11 project teams involved in this project. Virtual twins have become an indispensable asset in the aeronautics and mobility industries, where virtualization has enabled considerable progress in terms of safety, quality, ecological footprint and cost-effectiveness. MEDITWIN builds on the experience accumulated by the partners over many years in the field of virtual twins for healthcare, such as the Living Heart initiative by Dassault Systèmes (link), the Living Brain (link), as well as the activities of the PEPR digital health program co-directed by Inria and INSERM, for example. MEDITWIN will enable the industrialization, clinical validation and standardization of these innovations, so that these technologies can be deployed in a standardized way and benefit as many people as possible. The best standards of care will be incorporated into virtualized experiences made accessible worldwide, setting a new benchmark for quality in healthcare and providing a decisive learning ground for progress in medical science. The benefits of virtual twins will be assessed for medical teams, patients, and the healthcare system, notably in terms of improving the efficiency of care, quality of multidisciplinary decision-making, and effectiveness and safety of medical practices and interventions. In practice, the MEDITWIN initiative will be developed over five years, from 2024 to 2029. The partners' investment in this project will be financially supported by the French government as part of the “France 2030” plan. Partner quotes Bernard Charlès, Chairman of Dassault Systèmes “Virtual twins have successfully enabled the industrial world to transform itself more sustainably. Today, this technology is opening up new possibilities for healthcare by revealing the secrets of the human body - by understanding and representing the invisible. For 40 years, Dassault Systèmes has been a pioneer in virtual twins, and we can apply our knowledge and know-how to transform medical practice. The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare. The virtual twin is already a reality, and MEDITWIN will help standardize and disseminate it worldwide to benefit millions of patients.” Bruno Sportisse, CEO of Inria “Building an active digital ecosystem can only make France a European leader in digital healthcare innovation. In line with their strategic partnership signed in 2021, Inria and Dassault Systèmes are actively collaborating in the field of virtual twins in healthcare, with an aligned vision of the challenges of sovereignty and the digital transformation of healthcare. Supported by France 2030, the MEDITWIN project, resulting from ambitious collaboration between Dassault Systèmes, Inria and IHU France, demonstrates the commitment of these players to building a French industry at the forefront of emerging healthcare issues, all for the benefit of patients.” Fabrice André, CEO of IHU PRISM of Gustave Roussy “The MEDITWIN consortium is in line with PRISM's vision of developing cancer avatars to model biology at the patient level and tailor personalized therapies. PRISM will also benefit from the expertise of the other IHUs, and will be working closely with them to develop interdisciplinary projects.” Pierre JAIS, CEO of IHU LIRYC “Combining 7 IHUs, Inria and Dassault Systèmes, MEDITWIN is a remarkable public/private collaboration. This unique project opens a new era for scaled and automated preventive medicine, so critical for patients and immensely cost effective. Finally, it offers French doctors and researchers the opportunity of relying on a global industry champion in digital health for future medical research.” Pr. Didier Mutter, CEO, IHU Strasbourg “Virtual twins will be essential elements in the medicine of the future, as they will enable treatments to be simulated to provide patients with the best possible results. MEDITWIN is an exceptional project in terms of its ambition and the challenges to be met. It's also a premiere for the IHU France alliance, uniting a multidisciplinary biomedical research capability that has no parallel anywhere in the world. For IHU Strasbourg, it will be a powerful catalyst for improving the minimally invasive management of metastatic colorectal cancer, in close collaboration with two of its historical founders, Inria and the University Hospitals of Strasbourg.” Pr. Michel Paques, IHU FOReSIGHT, head of the ophthalmology 4 department and Director of the Clinical Investigation Center at the 15-20 national hospital “The integration of the FOReSIGHT IHU into the MEDITWIN consortium will enable the large-scale development of retinal microcirculation twins, enabling personalized detection and monitoring of cerebral and cardiovascular diseases in quantitative terms. This will be the first development of a quantitative microcirculatory biomarker. The FOReSIGHT IHU has developed expertise in innovative microvascular imaging using retinal imaging with adaptive optics, a technique in which France is a leader, with the help of French high-tech companies and research institutes. This approach, unique in the world, will be strengthened with Dassault Systèmes through the development of algorithms based in particular on AI to extract morphometric information from large retinal surfaces. The integration of these measurements into biomarkers that can be used directly by practitioners represents a major challenge for the transfer from the research laboratory to the consulting room.” Pr. Stanislas Lyonnet, CEO of Institut Imagine “Institut Imagine is proud to have been one of the initiators of the strategic partnership between Dassault Systèmes and Alliance IHU France on virtual twins. We are delighted to put our medical and research excellence in the field of rare diseases at the service of the MEDITWIN project. The first project, developed with Dassault Systèmes and INRIA, concerns cardiology, with a peri-surgical decision support system designed to drastically reduce the mortality rate of newborns suffering from congenital heart disease (Hypoplastic Left Heart Syndrome) thanks to a personalized virtual twin of the cardiovascular system. Our second project, developed in partnership with Dassault Systèmes and startup CODOC, concerns pediatric neurology, with a tool for managing the Multidisciplinary Board Meeting that uses a virtual twin of patients to aid medical decision-making and management of rare epilepsies, in particular Dravet syndrome. These two projects offer significant opportunities for researchers and doctors, who will be able to visualize, test, understand, and predict before experimenting on patients.” Pr. Alexis Brice, CEO of Paris Brain Institute, IHU ICM “We are delighted to collaborate closely with Dassault Systèmes and Inria within the IHU Alliance. We aim to structure an ecosystem of innovation in healthcare from which the medicine of tomorrow will emerge. The digital twin embodies the ambitions of the Institute's research: to streamline the use of health data at different scales, to model and predict the evolution of diseases, to diagnose early, and to build personalized medicine on a solid and reliable foundation. Within MEDITWIN, Paris Brain Institute will contribute its expertise in detecting Alzheimer's disease, vascular dementia and epilepsy, and in analyzing data from patient cohorts.” Pr. Stéphane Hatem, CEO of IHU ICAN and Director of the UMR 1166 Research Unit on Cardiovascular and Metabolic Diseases “Virtual twin technology opens up possibilities for novel precision and preventive medicine for cardiometabolic diseases. Its goal is to predict the personal future risk of developing a cardiovascular disease, based on individual risk pro especially the genomic signature. Such an ambition requires changing the scale of today’s research that will be achieved through the MEDITWIN project led by Dassault Systèmes and with all its partners on board.” Pr. Bertrand Cariou, Director of l’institut du thorax, CHU de Nantes “Nantes University Hospital, via ‘l’institut du thorax’, in collaboration with Dassault Systèmes engineers, will carry out developments aimed at improving the prediction of cardiovascular accidents, which represent the leading cause of mortality in industrialized countries. To achieve this goal, the researchers will use data from the SAFIR cohort, an outcome of the CHOPIN (CHOlesterol Personalized INnovation) nationwide translational research project, on patients with familial hypercholesterolemia with or without cardiovascular disease. This pilot study in a very high-risk cardiovascular population will combine clinical, multi-omics and imaging data to create a virtual twin model, which will then be validated in a larger cardiovascular population.” Todor Jeliaskov, CEO of inHEART “At inHEART, we are excited to be part of MEDITWIN and on the forefront of the digital health transformation. Within MEDITWIN, inHEART will focus on the prevention of Sudden Cardiac Death, which takes more than 800,000 lives each year. We need to move our healthcare systems from reacting to acute complications to preventing complications. Digital technologies and Artificial Intelligence are accelerating this process.” Arthur Delapalme, Co-founder and CEO of CODOC “The MEDITWIN project has succeeded in bringing together the medical expertise of several different University Hospital Institutes. In our view, this multidisciplinary approach is a fruitful way of accelerating research and rapidly bringing the benefits of innovations to patients. As CODOC, we are very proud to build one of the seven virtual twins of this project.” Stanley Durrleman, CEO of QAIRNEL “At Qairnel, we're proud to be part of the MEDITWIN project. Our virtual twins simulate the evolution of a patient in the early stages of Alzheimer's disease. The project will enable us to put these technologies into the hands of practitioners, to propose personalized management schemes and therapeutic strategies. This will enable us to respond to one of the major public health challenges of the 21st century.” Lionel Naccache, Co-Founder of Neurometers “Neurometers aims to generalize the medical use of the electroencephalogram (EEG) to quantify the cerebral signatures of consciousness and cognition. Initially developed in healthy subjects and non-communicative patients, with highly original results validated in numerous scientific publications, we have more recently discovered and reported that this approach could prove highly promising in the field of neurodegenerative diseases that impair cognition, such as Alzheimer's disease. For the first time, direct measures of cognitive functioning could be integrated into routine clinical monitoring of patients, complementing neuropsychological tests and measures of cerebral atrophy. This approach could also make it possible to evaluate the efficacy of new therapies. Our participation in the MEDITWIN project is aimed at improving the quality of our algorithms by analyzing a large cohort of patient EEG recordings in an evolutionary manner.” ### About France 2030 The France 2030 investment plan: Reflects a double ambition: sustainably transform key sectors of our economy (energy, automotive, aeronautics or space) through technological innovation, and position France not only as a player, but also as a leader in the world of tomorrow. From basic research, to the emergence of an idea to the production of a new product or service, France 2030 supports the entire life cycle of innovation until its industrialization. Is unpublished by its magnitude: €54 billion will be invested to ensure that our companies, universities and research organizations are fully successful in their transitions in these strategic sectors. The challenge: to enable them to respond competitively to the ecological and attractiveness challenges of the coming world, and to bring out the future champions of our sectors of excellence. France 2030 is defined by two cross-cutting objectives consisting in dedicating 50% of its spending to the decarbonization of the economy, and 50% to emerging players, who are the bearers of innovation without spending that is unfavorable to the environment (in the sense of the Do No Significant Harm principle). Will be implemented collectively: designed and deployed in consultation with economic, academic, local and European stakeholders to determine their strategic orientations and flagship actions. Project leaders are invited to submit their application via open, demanding and selective procedures to benefit from the support of the State. Is led by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Agency for Ecological Transition (ADEME), the French National Research Agency (ANR), Bpifrance and the Banque des Territoires. More information on: france2030.gouv.fr | @SGPI_avenir ### About Dassault Systèmes Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit Press contact: arnaud.malherbe@3ds.com About INRIA Inria is the French national research institute for digital science and technology. World-class research, technological innovation and entrepreneurial risk are its DNA. In 220 project teams, most of which are shared with major research universities, more than 3,900 researchers and engineers explore new paths, often in an interdisciplinary manner and in collaboration with industrial partners to meet ambitious challenges. As a technological institute, Inria supports the diversity of innovation pathways: from open source software publishing to the creation of technological startups (Deeptech). Press contact: laurence.goussu@inria.fr / magalie.quet@inria.fr About IHU PRISM and Gustave Roussy IHU Prism is based on a transformative vision of cancer care. It is supported by a consortium of five partners: Gustave Roussy, Université Paris-Saclay, CentraleSupelec, Inserm and Unicancer. Its aim is to better understand the biology of each patient's cancer, and to identify those with the most aggressive tumors as soon as they are diagnosed, in order to offer them a different care pathway, based on innovation, to maximize the chances of a therapeutic response. To achieve this, it relies on innovative tools and methodologies such as circulating marker analysis, artificial intelligence and organoids. Prism also aims to change the way in which cancer is viewed and classified, from an organ-based approach to a molecular one. Press contact: claire.parisel@gustaveroussy.fr About IHU Liryc Liryc is the only institute of its kind in the world dedicated to heart rhythm disorders. Liryc is committed to 4 missions: research, innovation, care and training. The aim is to gain a better understanding of the mechanisms behind these diseases, to develop therapeutic and diagnostic tools, to treat patients more effectively and to pass on the expertise acquired. Liryc brings together researchers, doctors, engineers and mathematicians from all over the world. In a unique technological environment and a dynamic ecosystem, Liryc is helping to invent the therapeutic tools of tomorrow, to meet this major public health challenge. It is one of seven university hospital institutes (IHU) created by the French government as part of the "Investissements d'Avenir" program, with the aim of boosting medical research and innovation in France. Its founders are the University of Bordeaux, the University Hospital of Bordeaux, Inria and the Nouvelle-Aquitaine region. Press contact: manon.hans@ihu-liryc.fr - 06 23 29 70 20 About IHU Strasbourg ( ) The IHU Strasbourg is a multidisciplinary institute dedicated to the creation and dissemination of innovative image-guided therapies for optimized, safe, and personalized patient care. Its goal is to establish a new standard of care for surgical patients, considering their entire treatment itinerary from preparation for surgery to their return to the norm, offering them the best possible quality of life. The Institute's missions focus on four key pillars: patient care, translational research, education and technology transfer. These missions encompass improving patients' quality of life, researching new treatments, developing innovative devices, and training and disseminating knowledge to support the ongoing evolution of the medicine of the future. Press contact: presse@ihu-strasbourg.eu About IHU FOReSIGHT Labeled IHU in 2019, the IHU FOReSIGHT aims to bring about the care of tomorrow in ophthalmology by accelerating research and access to therapeutic innovations. It was founded by the 15-20 National hospital, Sorbonne University, Inserm and the Fondation Voir et Entendre. It brings together expert centers in ophthalmology including the 15-20 National hospital and the Vision Institute of Paris, an international research center entirely dedicated to fundamental and translational research on vision diseases. Press contact: sylvie.jumel@institut-vision.org About Institut Imagine Located on the campus of the Necker-Enfants malades hospital, the Institut Imagine is a world leader in research, care and teaching on genetic diseases. Its unique architecture, designed by Jean Nouvel and Bernard Valéro, brings together 1,000 researchers, physicians, teacher-researchers, engineers and health care personnel in a single location to work with patients, with the ambition of accelerating research and diagnosis and therapeutic innovation to change the lives of families affected by genetic diseases. The Institut Imagine has been certified “Institut hospitalo universitaire” (IHU), in 2011 and 2019 and an “Institut Carnot”, in 2020. It is supported by six founding members, including AP-HP, Inserm and Université Paris Cité, as well as by private partners and patrons. Every day in France, 64 babies are born with a genetic disease. Nearly 8,000 genetic diseases affect more than 3 million people, of which nearly one in two is undiagnosed and more than 8 in 10 have no dedicated treatment. Faced with this public health emergency, the challenge is twofold: to diagnose and to cure. g Press Contact: marie.de-bazelaire@institutimagine.org About Institut du Cerveau Created in 2010, Paris Brain Institute is a leading scientific and medical research center dedicated to the study of the brain and the discovery of new treatments for diseases of the nervous system. Its innovative model brings together patients, doctors, researchers, and entrepreneurs with a common goal: to transform fundamental discoveries into therapeutic solutions via a translational and interdisciplinary approach. Located in Paris at the heart of the Pitié-Salpêtrière Hospital – the largest neurology center in Europe – Paris Brain Institute includes over 800 international experts in 27 research teams, ten cutting-edge technological platforms, a clinical investigation center, a training organization, a living lab, and a business incubator. It is based on the association of a joint research unit (Sorbonne University, Inserm, and CNRS) and a private foundation recognized as being of public utility, the ICM Foundation, in partnership with Assistance Publique–Hôpitaux de Paris. institutducerveau-icm.org Press contact: presse@icm-institute.org About IHU ICAN Created in 2011, located at the Pitié Salpêtrière Hospital, the Foundation for Innovation in CArdiometabolism and Nutrition (IHU ICAN) is a “Hospital-University Institute” and a center of excellence for translational research on cardiometabolic diseases such as diabetes, obesity, fatty liver disease (MASH), heart and vascular diseases. Our goal is to contribute to the emergence of a new personalized medicine that integrate the determinants that contribute to the risk of developing cardiometabolic diseases. With the support of its founders, the Greater Paris University Hospitals (AP-HP - Assistance Publique- Hôpitaux de Paris), the National Institute for Health and Medical Research (Inserm - Institut national de la santé et de la recherche médicale) and Sorbonne University (SU), ICAN has structured cutting-edge scientific platforms and unique expertise for translational research with a strong focus on multi-omic, new clinical imaging, data integration and artificial intelligence. IHU ICAN key figures: 170 physicians, 220 researchers, 50 active clinical trials, 6 rare disease reference centers, 4 innovative care pathways, over 6,000 scientific publications and overall more than 42,000 patients included in cohorts, registries and clinical trials. Today, ICAN is one of Europe's leading institutes for cardiovascular, metabolic and nutritional diseases, bringing together teams of basic and clinical researchers. Press contact: Francine Trocmé - f.trocme@ihuican.org About CHU de Nantes In the heart of Nantes, the University Hospital has nearly 13,000 employees who contribute to the promotion of the values of the public hospital service: equality, continuity, neutrality, and adaptability. With its nine establishments, the University Hospital of Nantes constitutes a center of excellence, healthcare recourses, and reference at both regional and interregional levels, while providing routine and local care to the 800,000 inhabitants of the Nantes/Saint-Nazaire metropolis. Located on the south bank of the Loire, a new hospital will come to fruition in 2027. It will be the foundation of the future health district, a project of European dimension. Created in 2004, l'institut du thorax is a translational research structure (CHU de Nantes/Inserm/CNRS/Nantes Université) dedicated to cardiac, vascular and metabolic diseases, combining research, clinical investigation and advanced training within a single organization. It aims at identifying genetic risk-factors, biomarkers and therapeutic targets to improve patient care, based on large, finely-documented bio-collections directly inspired by real-life patient experience and unmet medical needs. Press contact: Zakaria Gambert, zakaria.gambert@chu-nantes.fr, 07 77 25 95 47 Florane Pasquier, florane.pasquier@chu-nantes.fr, 02 53 48 28 11 About inHEART inHEART is a deep-tech healthcare startup based in Pessac, France. It’s a spin-off from INRIA, CHU de Bordeaux and Université de Bordeaux. The company develops web-based SaaS solutions for cardiologists by utilizing AI. inHEART leverages cardiac images and electrocardiograms uploaded by the physician to deliver a digital twin of the patient’s heart for cardiac arrhythmia treatment support and prevention/screening for cardiac diseases. The company has gathered substantial clinical evidence and received a Class II CE mark and 510(k) clearance. inHEART started commercializing its SaaS solution in 2022 and is rapidly growing its user base in Europe and the U.S., now available in over 140 hospitals. The company uses its vast amount of annotated clinical data to train powerful predictive AI software to prevent and screen for sudden cardiac death, stroke, and heart failure. These SaaS solutions will be released in several phases, starting in 2024.” Press Contact: Todor Jeliaskov, todor.jeliaskov@inheartmedical.com, 05 35 38 19 72 About CODOC CODOC is a healthtech company specializing in the development of business applications and the deployment of healthcare data warehouses. CODOC supports healthcare and research stakeholders in the reuse of healthcare data to accelerate research and improve patient care. Created in 2017, CODOC's solutions have proved their worth and are now deployed in some fifteen French hospitals and cited in over a hundred scientific publications. To find out more: Press contact: Mélissa Carballeda, +33 6 78 37 23 36, melissa@codoc.co About Qairnel Qairnel is a spin-off from Inria and the Paris Brain Institute. We launched docteurmemo.fr, the first digital clinic dedicated to memory impairments. Patients benefit from online screening tools and coordinated care pathways which rely on a network of partnering healthcare professionals. Generative AI tools predict the progression trajectory of each patient, and are used therefore to operate precision clinical trials faster and at lower costs with patients with well characterized progression pro Press contact: stanley.durrleman@qairnel.com About Neurometers Neurometers is a start-up company - a spin-off from the Institut du Cerveau in Paris, on the Pitié-Salpêtrière campus (APHP and Sorbonne University) - created as a result of the cognitive neuroscience work on consciousness carried out by Lionel Naccache (Sorbonne University, APHP) and Jacobo Sitt (INSERM) on healthy humans and patients suffering from disorders of consciousness. From an individual's electroencephalogram (EEG), cerebral signatures of cognition and state of consciousness are calculated and then used to train machine learning algorithms to identify a specific cognitive process or state of consciousness. Several studies have demonstrated the medical relevance of these algorithms, both in the field of consciousness disorders and in Alzheimer's disease. Press contact: lionel.naccache@icm-institute.org and jacobo.sitt@icm-institute.org View source version on businesswire.com: Contacts Dassault Systèmes Press contact: arnaud.malherbe@3ds.com Source: Dassault Systèmes View this news release online at:

Executive with Strong Track Record in Advancing Pipelines Through Clinical Development MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. “We are delighted to have Lorianne join our executive leadership team,” said Rick Pauls, DiaMedica’s President and Chief Executive Officer. “She is a board-certified neurologist and recognized clinical leader in the neurology with a demonstrated track record in progressing the development of therapeutics for multiple neuroscience indications. Having worked with several early and mid-stage companies, she is very experienced in clinical research and managing drug candidates through the clinical development and regulatory process. Her experience also includes playing a key role in the acquisition of multiple biotechnology companies. We welcome Lorianne and believe her extensive expertise will benefit us tremendously as our ReMEDy 2 trial for acute ischemic stroke is now recruiting patients.” “This is a very exciting time to join DiaMedica as it resumes enrollment in its ReMEDy2 trial,” said Dr. Masuoka, “I look forward to accelerating the development of DM199 and bringing a treatment option to the large number of ischemic stroke patients who currently have no good treatment options.” Dr. Masuoka has more than 25 years of experience building and expanding high value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances. She is a board-certified neurologist, experienced in treating stroke patients, who has successfully created and overseen high performing teams to lead the clinical development of new medicines, with a focus in neurology and oncology. Dr. Masuoka served as Chief Medical Officer of Epygenix Therapeutics, Marinus Pharmaceuticals (Nasdaq: MRNS), Cubist Pharmaceuticals ($9.5B acquisition by Merck), and Nektar Therapeutics (Nasdaq: NKTR) where, as a member of executive management, she managed teams in the areas of clinical research, pharmacovigilance, biostatistics and data management, regulatory affairs, and clinical operations. Previously, she held various roles of increasing responsibility at FivePrime Therapeutics ($1.9B acquisition by Amgen) and Chiron (now Novartis). In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc. ($516M acquisition by Ligand) and serves as a Board member at Opiant Pharmaceuticals (up to $500M acquisition by Indivior). Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and is board certified by the American Board of Psychiatry and Neurology. Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) In connection with Dr. Masuoka’s appointment, DiaMedica granted her an inducement stock option to purchase 285,000 shares of DiaMedica’s common stock pursuant to the DiaMedica Therapeutics, Inc. 2021 Employment Inducement Incentive Plan. The inducement grant was approved by the Company’s compensation committee of the board of directors and was effective as of Dr. Masuoka’s first date of employment, January 22, 2024, and was a material inducement to her acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of her compensation. About ReMEDy2 Trial The ReMEDy2 trial is an adaptive design, randomized, double-blind, placebo-controlled trial studying the use of the Company’s product candidate, DM199, to treat acute ischemic stroke (AIS) patients. The trial is intended to enroll approximately 350 patients at up to 100 sites globally. Patients enrolled in the trial will be treated for three weeks with either DM199 or placebo, beginning within 24 hours of the onset of AIS symptoms, with the final follow-up at 90 days. The trial excludes patients treated with tissue plasminogen activator (tPA) and/or mechanical thrombectomy. DiaMedica believes that the ReMEDy2 trial has the potential to serve as a pivotal registration study of DM199 in this patient population. About DM199 DM199 is a recombinant (synthetic) form of human tissue kallikrein 1 (KLK1). KLK1 is a serine protease (protein) that plays an important role in the regulation of diverse physiological processes including blood flow, inflammation, fibrosis, oxidative stress and neurogenesis via a molecular mechanism that increases production of nitric oxide and prostaglandin. KLK1 deficiency may play a role in multiple vascular and fibrotic diseases such as stroke, chronic kidney disease, retinopathy, vascular dementia, and resistant hypertension where current treatment options are limited or ineffective. DiaMedica is the first company to have developed and clinically studied a recombinant form of the KLK1 protein. The KLK1 protein, produced from the pancreas of pigs and human urine, has been used to treat patients in Japan, China and South Korea for decades. DM199 is currently being studied in patients with acute ischemic stroke (AIS). In September 2021, the FDA granted Fast Track Designation to DM199 for the treatment of AIS. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in China for the treatment of acute ischemic stroke and other vascular diseases, to be clinically studied in the United States. For more information visit the Company’s website at . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expectations. When used in this press release, the words “anticipates,” “believes,” “look forward,” “continue,” “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” or “will,” the negative of these words or such variations thereon or comparable terminology, and the use of future dates are intended to identify forward-looking statements. The forward-looking statements in this press release include statements regarding the anticipated clinical benefits and success of DM199 and the Company’s belief that the ReMEDy2 trial has the potential to serve as a pivotal registration study of DM199 in acute ischemic stroke patients. Such statements reflect management’s current view and DiaMedica undertakes no obligation to update or revise any of these statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, DiaMedica’s ability to conduct successful clinical testing of DM199 for the treatment of acute ischemic stroke and within its anticipated parameters, enrollment numbers, costs and timeframes, and other risks identified under the heading “Risk Factors” in DiaMedica’s annual report on Form 10-K for the fiscal year ended December 31, 2022 and subsequent U.S. Securities and Exchange Commission filings, including DiaMedica’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2023. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.